640 articles
AYUSH-PG tablet
AYUSH-PG tablet is a CCRAS coded Ayurvedic two-herb formulation (Gokshura, Punarnava) for pedal edema or pregnancy-induced hypertension during pregnancy, studied in Himachal Pradesh antenatal care trials and technology-transferred to industry.
Azelnidipine
Azelnidipine (CS-905, Calblock) is a third-generation dihydropyridine calcium channel blocker for hypertension, launched in Japan in 2003 and approved in China and India; it lowers blood pressure similarly to amlodipine but reduces heart rate instead of raising it.
Azilsartan
Azilsartan (azilsartan medoxomil, Edarbi) is the eighth angiotensin II AT1 receptor blocker approved for hypertension, FDA-approved 2011, dosed 80 mg daily, with greater SBP-lowering than valsartan and olmesartan and diarrhea as its most common adverse reaction.
Azilsartan medoxomil
Azilsartan medoxomil (TAK-491, Edarbi) is an angiotensin II receptor blocker prodrug for hypertension, FDA-approved February 2011; 40-80 mg once daily, hydrolyzed to active azilsartan, ranked most efficacious ARB at 80 mg.
Azimilide
Azimilide (NE-10064, azimilide dihydrochloride) is an investigational class III antiarrhythmic blocking both IKr and IKs potassium currents, developed by Procter & Gamble, tested in Phase 3 trials for atrial fibrillation and ICD patients but never approved.
Balaglitazone
Balaglitazone (DRF-2593) is a thiazolidinedione PPARγ partial agonist developed by Dr. Reddy's and Novo Nordisk for type 2 diabetes; its phase III BALLET trial showed HbA1c lowering with less edema than pioglitazone, but it was never marketed.
Balcinrenone
Balcinrenone, formerly AZD9977, is an oral nonsteroidal mineralocorticoid receptor modulator from AstraZeneca with partial antagonist activity intended to reduce hyperkalemia risk, now in phase 3 heart failure trials.
Bazedoxifene
Bazedoxifene (Conbriza, Duavee) is a third-generation SERM approved in the EU and Japan for postmenopausal osteoporosis, reducing vertebral fractures about 35-40% over 5 years; in the US it is sold only with conjugated estrogens.
Beclobrate
Beclobrate (CAS 55937-99-0), a clofibrate-analog fibric acid derivative antihyperlipidemic introduced in 1985; lowered LDL-C and triglycerides at 100 mg once daily; withdrawn in Switzerland in 1990 after fatal hepatitis reports.
Beinaglutide
Beinaglutide (贝那鲁肽, Yishengtai) is a short-acting GLP-1 receptor agonist, recombinant human GLP-1(7-36) with 100% human sequence, developed by Shanghai Benemae and approved in China in December 2016 for type 2 diabetes and weight management.
Beloranib
Beloranib (CKD-732, ZGN-440, ZGN-433): fumagillin-analogue MetAP2 inhibitor obesity drug by Zafgen and Chong Kun Dang; effective in trials but halted in 2015 after fatal pulmonary embolisms.
Bemiparin sodium
Bemiparin sodium (Hibor, Ivor, Zibor, Badyket) is a second-generation low-molecular-weight heparin from ROVI, mean MW 3,600 Da, anti-Xa/IIa ratio 8, once-daily subcutaneous prophylaxis and treatment of venous thromboembolism and hemodialysis anticoagulation.
Bempedoic acid
Bempedoic acid (Nexletol, Nilemdo; with ezetimibe as Nexlizet, Nustendi) is an oral ATP citrate lyase inhibitor lowering LDL-C; CLEAR Outcomes showed 13% fewer major cardiovascular events in statin-intolerant patients.
Benfluorex
Benfluorex (Mediator), a fenfluramine-derivative appetite suppressant and antidiabetic add-on drug marketed by Servier from 1976, withdrawn in France in 2009 and the EU in 2010 for causing 5-HT2B-mediated valvular heart disease.
Benfotiamine
Benfotiamine (S-benzoylthiamine O-monophosphate), a lipid-soluble synthetic thiamine (vitamin B1) derivative with higher bioavailability, activating transketolase; used for diabetic peripheral neuropathy in some countries and in trials for early Alzheimer's disease.
Benidipine
Benidipine (Coniel) is a Japanese dihydropyridine calcium channel blocker, launched in 1991 by Kyowa Hakko, that blocks L-, N-, and T-type calcium channels and treats hypertension and angina; trials show kidney benefits over amlodipine in CKD.
Benzarone
Benzarone, a benzofuran-derivative drug (C17H14O3) formerly used orally and topically for peripheral vascular disorders, withdrawn after severe idiosyncratic hepatotoxicity; structurally related to amiodarone and benzbromarone.
Benzbromarone
Benzbromarone (Desuric, Urinorm) is a benzofuran uricosuric drug first marketed in the 1970s to treat gout; it was withdrawn in Europe in 2003 over hepatotoxicity concerns.
Benzphetamine
Benzphetamine (Didrex) is a US Schedule III sympathomimetic amine anorectic, approved in 1960, used short-term with diet for obesity (BMI 30+), dosed 25-50 mg one to three times daily; brand discontinued, generics remain.
Benzthiazide
Benzthiazide is a thiazide diuretic of the same family as chlorothiazide, used to treat hypertension and edema; clinically evaluated in 1960, it has since been discontinued.
Beraprost
Beraprost (beraprost sodium), also sold as Dorner or Procylin, is the first orally active prostacyclin analogue, developed by Toray and approved in Japan in 1992 for chronic arterial occlusion and 1999 for primary pulmonary hypertension.
Berotralstat
Berotralstat (BCX7353, Orladeyo) is an oral once-daily plasma kallikrein inhibitor for prophylaxis of hereditary angioedema attacks, first FDA-approved December 3, 2020, now indicated for ages 2 and older.
Beta blocker
Beta blockers (beta adrenergic blocking agents) are drugs blocking beta-1/beta-2 adrenaline receptors, slowing heart rate and lowering blood pressure. Developed by James Black (propranolol, 1965; Nobel Prize 1988); used for angina, arrhythmia, heart failure, hypertension, glaucoma, migraine, anxiety.
Bethanidine
Bethanidine (betanidine, B.W. 467C60, Esbatal) is a guanidinium sympatholytic antihypertensive, C10H15N3, half-life 9 hours, approved in the UK in 1963 and later discontinued; it resembled guanethidine but caused no diarrhea.
Betrixaban
Betrixaban, sold as Bevyxxa, is an oral direct factor Xa inhibitor approved by the FDA in 2017 to prevent venous thromboembolism in hospitalized adults with limited mobility.
Bevifibatide citrate (formerly batifiban)
Bevifibatide citrate (formerly batifiban, 贝塔宁/BETAGRIN) is a cyclic peptide GPIIb/IIIa and αvβ3 dual-target antiplatelet drug approved in China in June 2024 for ACS patients undergoing PCI, with Phase III composite endpoint HR 0.57.
Bexagliflozin
Bexagliflozin (Brenzavvy; Bexacat in cats) is an SGLT2 inhibitor approved by the FDA on January 20, 2023, dosed 20 mg daily as adjunct to diet and exercise for adult type 2 diabetes, notable for low cost and no cardiovascular outcomes trial.
Bezafibrate
Bezafibrate is a fibrate-class lipid-lowering drug, available in Europe since 1977 under trade names including Bezalip, used as an adjunct to diet when statins are contraindicated.
BGM0504
BGM0504 is BrightGene's investigational once-weekly injectable dual GLP-1/GIP receptor agonist for obesity and type 2 diabetes, with phase 3 weight loss of 19.3% and an NDA accepted in China in June 2026.
BGR-34
BGR-34 (NBRMAP-DB) is an Ayurvedic six-herb tablet for type 2 diabetes developed by CSIR-CIMAP and CSIR-NBRI, licensed to AIMIL Pharmaceuticals, sold in India since 2015 amid disputed clinical evidence.